VANCOUVER, British Columbia–(BUSINESS WIRE)–Life Sciences BC (LSBC) is pleased to announce new and returning members to the Board of Directors following its Annual General Meeting (AGM) on September 17, 2025. The Board of Directors is comprised of seasoned leaders dedicated to driving forward the growth of the life sciences sector. New and Returning Board Members … [Read more…]
Now supporting residents at Legacy Pointe as partnerships continue to grow LOS ANGELES–(BUSINESS WIRE)–#AI–Cairns Health, a healthcare technology company pioneering AI-enabled conversational companion and remote monitoring solution, is pleased to announce the expansion of its commercial launch of Luna, with the addition of Legacy Pointe at University of Central Florida (UCF). Legacy Pointe at University … [Read more…]
MILFORD, Conn.–(BUSINESS WIRE)–#SOC2–PBIRx, Inc., a national leader in pharmacy benefit consulting and auditing, is proud to announce exciting updates reflecting the growth and strength of its Clinical Operations team. Andrew Reis, RPh, MBA has been named Director of Clinical Consultants. With over 20 years of experience in pharmacy benefit management, Andrew brings deep industry knowledge … [Read more…]
Unified Brand and Lucet™ at Home Reflects the Integration of Lucet and Emcara Health and a Shared Commitment to Expanding Access and Improving Clinical Outcomes. OVERLAND PARK, Kan.–(BUSINESS WIRE)–Lucet, a leader in behavioral health, combining advanced technology with clinical expertise and compassionate, whole-person care, today announced its brand evolution, symbolizing the union of Lucet and … [Read more…]
~ Agreement grants VectorY the exclusive right to evaluate and license Shape’s non-invasive, deep-brain penetrating AAV5-derived capsid for vectorized antibodies against three targets ~ ~ License will enable the advancement of VectorY’s pipeline of transformative neurodegenerative disease programs ~ AMSTERDAM & BOSTON & SEATTLE–(BUSINESS WIRE)–#ALS–VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for … [Read more…]
Results of the POSITIVE study assessing the treatment with tildrakizumab showed sustained improvements in skin clearance, psychological well-being, and improved partner quality of life in adults with moderate-to-severe psoriasis over two years. POSITIVE is the first real-world evidence (RWE) study in dermatology to use the WHO-5 Well-Being Index as a primary endpoint, complementing traditional measures … [Read more…]
Cetaphil’s new Skin Activator Hydrating & Firming Line harnesses a proprietary formula, co-created with dermatologists and offering targeted, high-performance skincare designed to improve the appearance of skin affected by dermatoporosis The line’s new Skin Activator technology uses microdosed alpha hydroxy acid (AHA) and encapsulated centella asiatica (CICA) to wake up sleeping surface skin cells To … [Read more…]
Device is designed to work in tandem with Ruthless Spine’s De Novo cleared RJB™ intraoperative angle measurement instrument LOS ANGELES–(BUSINESS WIRE)–Ruthless Spine today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NavJam™ Jamshidi device, and as of today, U.S. Patent Office records indicate that the status of the … [Read more…]
Empowering professionals with faster, smarter, and trusted research capabilities through generative AI and 60+ years of domain expertise SYDNEY–(BUSINESS WIRE)–Wolters Kluwer Tax and Accounting (TAA) Asia Pacific (APAC) today announced significant AI-powered advancements to its award-winning CCH iKnowConnect research platform, further transforming how tax and legal professionals access and apply information. The latest release introduces … [Read more…]
Vimseltinib is the first and only therapy with marketing authorization for the treatment of TGCT in the European Union OSAKA, Japan & WALTHAM, Mass.–(BUSINESS WIRE)–Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Commission (EC) has approved ROMVIMZA™ (vimseltinib) in the European Union (EU) for the … [Read more…]
